{"url_path":"/sec/avr/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/2011514/0001140361-26-020806-index.html","accession_number":"0001140361-26-020806","cik":"0002011514","ticker":"AVR","issuer_name":"Anteris Technologies Global Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2011514/0001140361-26-020806-index.html","primary_entity_key":"0002011514","primary_entity_name":"Anteris Technologies Global Corp."},"word_count":1264,"has_tables":true,"body_markdown":"UNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\nFORM 10-Q\n\n(Mark One)\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the Quarterly Period Ended March 31, 2026\n\n \n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nCommission File Number 001-42437\n\n \n\nAnteris Technologies Global Corp.\n\n(Exact name of Registrant as specified in its Charter)\n\n \n\nDelaware\n\n \n\n99-1407174\n\n(State or other jurisdiction of incorporation or organization)\n\n \n\n(I.R.S. Employer Identification No.)\n\n \n\nToowong Tower, Level 3, Suite 302\n\n9 Sherwood Road\n\nToowong, QLD\n\nAustralia\n\n \n\n4066\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area code: +61 7 3152 3200\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon stock, par value $0.0001 per share\n\n \n\nAVR\n\n \n\nThe Nasdaq Global Market\n\n \n\nIndicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\nYES ☒ NO ☐\n\n \n\nIndicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☒\n\n \n\n \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\nYES ☐ NO ☒\n\n \n\nThe number of shares outstanding of the registrant’s Common Stock as of May 11, 2026 was 97,342,203.\n\n \n\n1\n\n \n\nANTERIS TECHNOLOGIES GLOBAL CORP.\n\n \n\nFORM 10-Q\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\nTABLE OF CONTENTS\n\n \n\n \n \n \n \n\n \n \n\nPage\n\n \n \n \n\n**PART I FINANCIAL INFORMATION**\n\n1\n\n \n \n \n\n \n\n[Item 1. Financial Statements (Unaudited)](#F)\n\n1\n\n \n \n \n\n \n \n\n[Condensed Consolidated Statements of Operations](#OPERATIONS)\n\n1\n\n \n \n \n\n \n \n\n[Condensed Consolidated Statements of Comprehensive Loss](#COMPREHENSIVE_LOSS)\n\n2\n\n \n \n \n\n \n \n\n[Condensed Consolidated Balance Sheets](#BALANCE_SHEETS)\n\n3\n\n \n \n \n\n \n \n\n[Condensed Consolidated Statements of Stockholders’ Equity](#EQUITY)\n\n4\n\n \n \n \n\n \n \n\n[Condensed Consolidated Statements of Cash Flows](#CASH_FLOWS)\n\n5\n\n \n \n \n\n \n \n\n[Notes to the Condensed Consolidated Financial Statements](#NOTES)\n\n6\n\n \n \n \n\n \n\n[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#Managements)\n\n12\n\n \n \n \n\n \n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#Quantitative)\n\n17\n\n \n \n \n\n \n\n[Item 4. Controls and Procedures](#Controls)\n\n17\n\n \n \n \n\n[PART II OTHER INFORMATION](#PART_II)\n\n17\n\n \n \n\n \n\n[Item 1. Legal Proceedings](#Item_1)\n\n17\n\n \n \n \n\n \n\n[Item 1A. Risk Factors.](#Item_1A)\n\n17\n\n \n \n \n\n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item_2)\n\n18\n\n \n \n \n\n \n\n[Item 3. Defaults Upon Senior Securities](#Item_3)\n\n18\n\n \n \n \n\n \n\n[Item 4. Mine Safety Disclosures](#Item_4)\n\n18\n\n \n \n \n\n \n\n[Item 5. Other Information](#Item_5)\n\n18\n\n \n \n \n\n \n\n[Item 6. Exhibits](#Item_6)\n\n18\n\n \n\n2\n\n[Table of Contents](#TO)\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\n \n\nAll statements in this Form 10-Q, other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, product development, and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are subject to risks, include, but are not limited to, statements about:\n\n \n\n●\n\nour current and future research and development (“R&D”) activities, including clinical testing and manufacturing and related costs and timing;\n\n \n\n●\n\nour product development and business strategy, including the potential size of the markets for our products and future development and/or expansion of our products in our markets;\n\n \n\n●\n\nour ability to commercialize products and generate product revenues;\n\n \n\n●\n\nany statements concerning anticipated regulatory activities, including our ability to obtain regulatory clearances;\n\n \n\n●\n\nour R&D expenses;\n\n \n\n●\n\nsufficiency of our capital resources;\n\n \n\n●\n\nour ability to raise additional funding when needed; and\n\n \n\n●            risks facing our operations and intellectual property.\n\n \n\nWe have based the forward-looking statements contained in this Form 10-Q largely on our current expectations, estimates, forecasts and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 26, 2026 (the “Annual Report”), as such risks and uncertainties may be amended, supplemented or superseded from time to time by our subsequent reports on Forms 10-Q and 8-K we file with the SEC, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.\n\n \n\nThe forward-looking statements made in this Form 10-Q relate only to events as of the date on which the statements are made. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended do not protect any forward-looking statements that we make within this Form 10-Q.\n\n \n\nYou should read this Form 10-Q and the documents that we reference in this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Form 10-Q by these cautionary statements.\n\n \n\nThis Form 10-Q contains certain data and information that we obtained from various publications. Statistical data in these publications also include projections based on a number of assumptions.\n\n \n\nAll references in this Form 10-Q to our common stock, par value $0.0001 per share (“Common Stock”) shall include the shares represented by CHESS Depository Interests (“CDIs”), each of which represents one underlying share of Common Stock, unless the context suggests otherwise. In addition, the nature of the medical technology industry results in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of our industry. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.\n\n \n\n3\n\n[Table of Contents](#TO)\n\nPart I. Financial Information"}